Day 1 :
Keynote Forum
Paula Hodgson
The Chinese University of Hong Kong, Hong Kong
Keynote: Personalized medication advice using mobile apps
Time : 10:30-11:15
Biography:
Abstract:
Keynote Forum
Karen Cusack
Health Complaints Commissioner Victoria, Australia
Keynote: Healthcare errors and patient redress: How can complaints and patient health informatics improve quality?
Time : 11:30-12:15
Biography:
Karen Cusack was appointed as Victoria’s Inaugural Health Complaints Commissioner in 2017 to oversee complaints resolution processes about health services as well as for conducting investigations into providers who pose a risk to Victorians. Prior to heading up the HCC, she was corporate Counsel of The Royal Women’s Hospital and has over 20 years’ of experience as a Senior Lawyer. She holds a Master in Laws from Monash University. She has been on a number of boards and was appointed by an expert working group advising on legislative reforms from “Targeting Zero: review of hospital safety and quality assurance in Victoria”.
Abstract:
Keynote Forum
Dean Rakic
NovaTec Consul􀆟ng, Stu􀆩gart, Germany
Keynote: Adopting interoperability – Blockchain solution for healthcare
Time : 12:15-13:15
Biography:
Abstract:
Keynote Forum
Sjaak Vink
CEO and Founder of TheSocialMedwork, Netherlands
Keynote: Accelerating global access to health innovatio
Time : 16:00 - 16:45
Biography:
Sjaak is the founder and CEO of TheSocialMedwork. He is a social innovator aiming to create a more equal and fair healthcare system that will give everyone, everywhere the same choices. Also the founder and former CEO of myTomorrows, he has further involvement in patient advocate groups such as the Abigail Alliance in Washington DC and Chicago based Cures Within Reach. Later on Sjaak initiated the Global Manifesto for Entrepreneurial Social Impact Change. In 2011 it was signed in Amsterdam by 600 successful young entrepreneurs from all over the world as a commitment to building social impact into the DNA of their companies. Today he remains an active part of TheSocialMedwork, sharing the work fl oor with a team of dedicated colleagues.
Abstract:
What is the challenge? Healthcare access is a worldwide challenge. Every day, patients from all over the world are denied access to elsewhere approved health innovations for arbitrary reasons. It is concerning to know that the number of cancer deaths is growing globally year aft er year with 3 out of 5 people aff ected with the disease around the world. I have also been there myself. I experienced personal hardships of family members and acquaintances that passed away before ever accessing the medicines they needed. My dear friend Stephan who was also an ALS patient, passed away before accessing the latest elsewhere approved treatments that could have easily prolonged his life. His only wish was to have “More tomorrows”. Why Now? Th e creation of Th eSocialMedwork is a timely and critical one, with only 11 years separating us from the 2030 health targets of the United Nations. It is our responsibility and duty to eradicate this challenge as soon as possible. Our aim is to keep pushing for a change in the access to healthcare landscape every single day. We have now safely delivered over 5,500 latest innovative medicines to over 75 countries, years before the offi cial availability in these countries. How are we doing it? Under the Named Patient import basis, Th eSocialMedwork is safely and legally delivering medicines to all over the world. Th ese regulations allow every citizen and healthcare provider to legally import an elsewhere approved treatment into their country of residence. Our success could not be achieved without a highly qualifi ed and skilled multicultural team which includes doctors, pharmacists, medical industry experts, scientists, regulatory experts and lawyers. We focus on the latest innovative medicines in oncology, neurology and rare diseases. We work on behalf of the patient in cooperation with their treating doctor or on behalf of expert hospital pharmacies and professors at centers of excellence. We oversee the entire process of sourcing and delivering the medicine so that the patient, doctor or pharmacy does not have to. In every case, patients must possess a prescription from their treating doctor based in their country of residence. Treatment responsibility should always be with the treating doctor. Our online platform is catered to both patients and healthcare professionals. Th ey are able to browse through diff erent treatments and discover the latest trials and approval process. It is also a place of support and inspiration where they can read other patients’ experiences living with a particular illness. What happens next? Th eSocialMedwork’s end goal is global health access for everyone regardless of their fi nancial situation. Th is is why we are working towards crowd funding, blockchain transparency, pricing algorithms and conditional reimbursement pilots. In the future we aim to further work together with pharma companies, patient organisations and healthcare professionals to provide patients with the latest and most innovative treatments at their fi ngertips the second they become approved around the world.
- e-Health | Digital Health Start-up Forum | E-Health Applications | Electronic Health Records | Telemedicine | Consumer Health Informatics | Health IT Systems | Virtual Healthcare | Health Data Security | Medical Devices |e–Prescription | Bioinformatics and Digital Health | Diabetes and digital health | Healthcare Innovations |Next-generation sequencing | Artifi cial intelligence | Virtual Reality
Session Introduction
Ersin AKPINAR
Cukurova University, Adana - Turkey
Title: Accelerating health care to Orthorexia Nervosa and Obsessivecompulsive Symptomatic high school students
Time : 14:00-14:30
Biography:
Ersin AKPINAR has completed his specialty training in Family Medicine at Adana Numune Research and Training Hospital. He started working at Cukurova University's Medical Faculty Department of Family Medicine in January 2000 and was appointed as a Full Clinical Professor of Family Medicine in 2013. He studied at The Universite Libre de Bruxelles in Brussels between 2004-2005 and then at the University of Illinois at Chicago in 2005 for a period of two months fellowship in Clinical Decision making fellowship, following his study in Akademisches Lehrkrankenhaus der Universität Duisburg-Essen Sankt Clemens Hospitale Sterkrade in 2010 later he went Germany for the project of the research and residency education needs for improving the quality of gastrointestinal diseases care in family medicine and at last he completed his study at University of Michigan at United States in 2014 for a period of three months. The main areas of his interest are primary care of acute and chronic diseases, hypertension, cardiovascular risk analysis, sexuality, and sexual dysfunctions, medical education, learning models, the electronic patient record programs, social media, digital health and innovation. He still works on many university-funded research projects.
Abstract:
The term of ‘eating disorders’ (EDs) covers the variety of disorders that are characterized by the abnormal eating habits of the patient associated with emotional diffi culties. Orthorexia nervosa (ON) is mainly characterized by supreme obsession with eating healthy, that sometimes lead to the severe physical, psychological and social disorders. Many of the psychological and behavioral aspects of EDs are shared by people who are at risk of ON. A signifi cant correlation between ON and the psychopathological characteristics of other EDs, was observed based on the variables including drive for thinness, bulimia symptoms, body dissatisfaction, perfectionism, interoceptive awareness, asceticism and impulsiveness. Thus, highlighted the possible relation between the risk of suffering ON and the diagnosis of ED.
Oluwadamilola Oshodi
University of South Florida, USA
Title: The future of medicine is now: Nanotechnology
Time : 14:30-15:00
Biography:
Oluwadamilola Oshodi is a student at the University of South Florida, persuing her Master’s in Pharmaceutical Nanotechnology. With a background in Biology and Communication Arts, she has made it her duty to make the complexities of science digestible to all people. She is not only a student but the creator of a podcast and an online community called The Plannter which focuses on helping millennials grow into the best version of themselves. She is also the owner and creator of Made for Nano, a platform that helps educate people on the importance of nanomedicine, create opportunities to network with other nanomedicine enthusiasts, and foster relationships to create greater collaborations within the field.
Abstract:
Many healthcare professionals are not aware of nanomedicine and how it can transform healthcare practices. Many are not given the opportunity to learn the basics of nanotechnology, specifi cally in nanomedicine and how it can apply to their practices, businesses, and health. The purpose of this presentation is to give an introduction of nanotechnology and a basic understanding of its various purposes in modern medicine. It will provide an understanding of the functionality and characteristics of nanoparticles and how these details can be manipulated to enhance nanoparticle functions in general therapeutic applications. This presentation will also examine current drugs on the market and future possibilities with nanomedicine. For instance, applications of nanoparticles towards regenerative medicine can improve tissue engineering and ease the effects of diseases like osteoarthritis. In addition, targeted drug delivery systems using nanomedicine can be a solution to current conventional drug delivery options. As healthcare professionals are introduced to new ideas and methods in nanomedicine, they can understand what’s possible for their practice and provide the best care possible to their patients. Many healthcare professionals are not aware of nanomedicine and its possibilities for the future of medicine. A basic understanding of nanotechnology on general therapeutic applications such as targeted drug delivery systems and regenerative medicine can transform current healthcare practices and provide professionals with tools to advance patient care.
Andrea Giovanni Migliavacca
Think4Future Srl, Milan, Italy
Title: AMONTRACk- mHealth app to support Parkinson's patients to be more engaged
Time : 15:00-15:30
Biography:
Andrea Giovanni Migliavacca has 22-year of experience in ICT Field. As a Senior Consultant for international organizations (ONUDI, IADB), he has gained international experience. Since 2009, he served as Senior Consultant and Project Manager at Lombardia Informatica where he has also worked in several eHealth projects, leading the team in the SALUS project. Besides managing eHealth projects, he has also worked as Management Consultant in SMEs around Italy. He holds a degree in Business Administration (1988). He is the Founder and the CEO of Think4Future. Based on his experience in several eHealth projects, he has conceived and designed the LifeCharger system.
Abstract:
AMONTRACk, project co-funded by the Lombardy, saw the collaboration between Think4Future and the Casa di Cura del Policlinico to test LifeCharger, an app to support the chronic patient in the management of his/her therapies. Parkinson's disease is a chronic neurodegenerative disease with an evolutionary character that is characterized by the presence of bradykinesia, tremor, rigidity and other motor and non-motor symptoms. The onset of Parkinson's disease is usually asymmetric and has an excellent response to dopaminergic drug therapy. From the early stages of the disease, close monitoring of the patient's proper drug intake is necessary to avoid the occurrence of motor blocking or dyskinesias. Over time the therapy must be personalized continuously based on the characteristics of the patient, the stage of illness and the functional request of the same. This condition, among the chronic diseases, is particularly suitable for testing LifeCharger, as an instrument able to monitor not only the right therapy but also the presence of pathognomonic signs and symptoms of the disease and its development, supporting the clinician in his therapeutic choices with specifi c and useful reports. Thanks to this monitoring, also factors related to the autonomy of everyday life can be corrected where necessary, aiming for a better quality of life and optimization of the therapeutic response. For chronic Parkinson's patients, there is a close correlation between the correct intake of therapies and the occurrence of symptoms. Allowing the patient to record these events with precision, also with the support of the caregiver, the treating physicians can modulate more precisely the therapies or the possible temporal scan of the same.
Michael Hession
Western Sydney University, Australia
Title: Gaming National Emergency Access Target (NEAT) performance using Emergency Treatment Performance (ETP) defi nitions and ED short stay units.
Time : 15:30-16:00
Biography:
Michael Hession is a full time Emergency Physician with Master’s degrees in Biomedical Engineering and Business Administration. He has an interest in Modelling of Performance Measures. He also has published an article on home telemonitoring in obstructive airways disease.
Abstract:
Objective: The objective of the present study is to evaluate potential gaming of the four-hour metric known as the National Emergency Access Target (NEAT) in Australia and Emergency Treatment Performance (ETP) in NSW. Methods: Descriptive statistical analysis was used to recalculate and compare the scores for NEAT and the NSW ETP metric with 32,148 presentations during 2016. The effect on the ETP score of a reclassifi cation of patients was assessed. A computer simulation using a discrete event model illustrated the effect of the use of ED short stay beds on the ETP scores. Results: Using the ETP timestamp of the intent to discharge a patient, called, ‘ready for departure’ instead of the time of physically leaving the department which is used in the NEAT defi nition, resulted in an apparent 6% performance improvement. A local interpretation of the NSW state defi nition of the ‘transferred’ patient resulted in the ETP for ‘admitted’ patients improving by 16%. The discrete event model demonstrated that without changing patient length of stay, ETP scores can be improved by or optimizing the time of the admit decision or increasing the number of ED short stay beds. Conclusions: The opportunity of NEAT may be squandered unless gaming of the defi nitions and use of ED short stay beds is addressed. We argue that the longstanding issue of ‘departure time’ should be defi ned as ‘physically leaving’ the department which is a real measure of ED resource use and that NSW and national recommendations should be adjusted. ACEM accreditation of EDs should include review of their application of NEAT defi nitions so that they truly refl ect patient fl ow processes. Biography